Xiao-yong Zheng1, Ri-bao Wei, Suo-zhu Shi, Zhong Yin, Xiang-mei Chen. 1. Nephropathy of Chinese PLA General Hospital, State Discipline and Key Laboratory of Kidney Disease-Chinese PLA General Hospital 2011DAV00088, Beijing 100853, China.
Abstract
OBJECTIVE: To investigate the impact of a traditional Chinese medicinal compound known as Fufang Shenhua Tablet (SHP) on the expression of Toll-like receptors (TLRs) during renal ischemia-reperfusion injury (IRI)-induced acute kidney injury (AKI) in rats. METHODS: A total of 28 Wistar rats were randomly divided into five groups: (1) pseudo-operation control group, (2) ischemia-reperfusion model group, (3) Astragaloside group, (4) high-dose SHP group, and (5) low-dose SHP group. There were four rats in the pseudo-operation group and six rats in each of the other groups. The accepted ischemia-reperfusion model was established after a 7-day gavage intervention, and pathological changes and renal function were observed, using an enzyme-linked immunosorbent assay (ELISA) to detect interleukin 8 (IL-8) and interferon gamma (IFN-γ) levels, as well as immunohistochemical staining to detect altered levels of TLR2 and TLR4 expression in renal tissue. RESULTS: After 24 h, renal pathological damage and the expression levels of serum creatinine (Scr), IL-8, IFN-γ, TLR2, and TLR4 were significantly higher in the model group as compared with the pseudo-operation group (P<0.05). In addition, at 24 h the above indicators decreased significantly in the Astragaloside group, high-dose SHP group and low-dose SHP group as compared with the ischemia-reperfusion model group (P< 0.05). TLR2 and TLR4 expression levels were significantly reduced in the SHP treatment and Astragaloside group as compared with the pseudo-operation group (P<0.05). Further, the high-dose SHP group showed significantly less renal damage score and decreased levels of TLR expression than those of low-dose SHP group and Astragaloside group (all P<0.05). CONCLUSION: SHP can alleviate the renal structural and functional damage caused by IRI-induced AKI in rats by reducing the damage of renal pathology, which may reduce inflammatory cytokine levels by downregulating the expression of TLRs in renal tissue in a dose-dependent manner.
OBJECTIVE: To investigate the impact of a traditional Chinese medicinal compound known as Fufang Shenhua Tablet (SHP) on the expression of Toll-like receptors (TLRs) during renal ischemia-reperfusion injury (IRI)-induced acute kidney injury (AKI) in rats. METHODS: A total of 28 Wistar rats were randomly divided into five groups: (1) pseudo-operation control group, (2) ischemia-reperfusion model group, (3) Astragaloside group, (4) high-dose SHP group, and (5) low-dose SHP group. There were four rats in the pseudo-operation group and six rats in each of the other groups. The accepted ischemia-reperfusion model was established after a 7-day gavage intervention, and pathological changes and renal function were observed, using an enzyme-linked immunosorbent assay (ELISA) to detect interleukin 8 (IL-8) and interferon gamma (IFN-γ) levels, as well as immunohistochemical staining to detect altered levels of TLR2 and TLR4 expression in renal tissue. RESULTS: After 24 h, renal pathological damage and the expression levels of serum creatinine (Scr), IL-8, IFN-γ, TLR2, and TLR4 were significantly higher in the model group as compared with the pseudo-operation group (P<0.05). In addition, at 24 h the above indicators decreased significantly in the Astragaloside group, high-dose SHP group and low-dose SHP group as compared with the ischemia-reperfusion model group (P< 0.05). TLR2 and TLR4 expression levels were significantly reduced in the SHP treatment and Astragaloside group as compared with the pseudo-operation group (P<0.05). Further, the high-dose SHP group showed significantly less renal damage score and decreased levels of TLR expression than those of low-dose SHP group and Astragaloside group (all P<0.05). CONCLUSION:SHP can alleviate the renal structural and functional damage caused by IRI-induced AKI in rats by reducing the damage of renal pathology, which may reduce inflammatory cytokine levels by downregulating the expression of TLRs in renal tissue in a dose-dependent manner.
Authors: Amandeep Bajwa; Sang-Kyung Jo; Hong Ye; Liping Huang; Krishna R Dondeti; Diane L Rosin; Volker H Haase; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa Journal: J Am Soc Nephrol Date: 2010-03-25 Impact factor: 10.121
Authors: Byung Soo Kim; Sun Woo Lim; Can Li; Jung Shim Kim; Bo Kyung Sun; Kyung Ohk Ahn; Sang Woo Han; Jin Kim; Chul Woo Yang Journal: Transplantation Date: 2005-05-27 Impact factor: 4.939
Authors: Huiling Wu; Gang Chen; Kate R Wyburn; Jianlin Yin; Patrick Bertolino; Josette M Eris; Stephen I Alexander; Alexandra F Sharland; Steven J Chadban Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808
Authors: Thiruma V Arumugam; Eitan Okun; Sung-Chun Tang; John Thundyil; Stephen M Taylor; Trent M Woodruff Journal: Shock Date: 2009-07 Impact factor: 3.454